TBCK (TBC1 domain-containing kinase) antibodies are essential tools in studying the TBCK protein, a conserved kinase implicated in cellular signaling pathways, particularly those regulating cell growth, autophagy, and mTOR (mechanistic target of rapamycin) signaling. The TBCK protein contains a kinase domain and a TBC (Tre-2/Bub2/Cdc16) domain, typically associated with GTPase-activating protein (GAP) activity, though its precise biochemical function remains under investigation.
Mutations in the *TBCK* gene are linked to rare neurodevelopmental disorders characterized by intellectual disability, hypotonia, and progressive brain atrophy. Research using TBCK antibodies has revealed its role in neuronal development and survival, with loss-of-function mutations disrupting lysosomal homeostasis and mTORC1 signaling. These findings highlight TBCK's potential as a therapeutic target for neurodegenerative conditions.
TBCK-specific antibodies, including monoclonal and polyclonal variants, are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect protein expression, localization, and post-translational modifications. Recent studies also employ CRISPR-engineered cell lines and animal models validated with TBCK antibodies to explore disease mechanisms. Despite progress, challenges persist in fully elucidating TBCK's interactome and downstream effectors, driving continued demand for high-affinity, well-characterized antibodies to advance functional and translational research.